



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 01/29/2008 12:10  
**Last Report Issued** 02/21/2007 07:27

**88888**

IS TESTING ACCOUNT  
Attn: IS Department  
200 Welsh Road  
Horsham, PA 19044-2208

**Patient Name** 1812SP-POS  
**Patient ID** 1812SP-POS  
**Chain 1**  
**Age** Not Given **Gender** Not Given

**Workorder** 07000294  
**Received** 02/21/2007 07:25

**Sample ID** 07000294-001  
**Matrix** Serum or Plasma  
**Patient Name** 1812SP-POS  
**Patient ID** 1812SP-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**1812SP Donepezil, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Donepezil	5000	ng/mL	1.0	
Synonym(s): Aricept®				

Acetylcholinesterase inhibition (50%-90%) has been observed at steady-state plasma concentrations between 15 - 50 ng/mL. Steady-state levels are achieved after approximately 2 weeks of daily dosing.